An update on clinical surfactant preparations and respiratory disease

The pulmonary surfactant and respiratory disease are tightly linked. Adequate surfactant activity remains critical for optimal lung function throughout life, and secondary surfactant dysfunction may contribute to the process of many lung diseases, including Acute Respiratory Distress Syndrome, asthma, cystic fibrosis and pneumonia among others. Attempts to treat these lung diseases with exogenous surfactants have been only partially successful. The objective of this article is to carry out an update on clinical surfactant preparations and immunomodulatory properties, as well as all related to clinical trials of clinical surfactant preparations and respiratory diseases in the pharmaceutical market today. The results show the potential to extent the use of the exogenous surfactant preparations to other respiratory disease different than Neonatal Respiratory Disease Syndrome. The importance of immunomodulatory functions of lung surfactant and the aim to evaluate the effectiveness of including different drugs as ingredient of a surfactant preparation represent the research’s active field on surfactant topic.